News

Supernus Reports Encouraging Phase 2a Results for SPN-820

Supernus Reports Encouraging Phase 2a Results for SPN-820

Supernus Pharmaceuticals Showcases SPN-820 Study Results

Supernus Pharmaceuticals, Inc. has recently shared promising findings from its exploratory open-label Phase 2a clinical study of SPN-820, a novel treatment for major depressive disorder (MDD), presented at Psych Congress 2024. This biopharmaceutical company is dedicated to advancing therapies for central nervous system (CNS) diseases, and the data indicates significant improvements in depressive symptoms among participants.

Rapid Improvement in Depressive Symptoms

The Phase 2a trial involved 40 subjects diagnosed with MDD. The treatment consisted of administering 2400 mg of SPN-820 every three days as an adjunct to their existing antidepressant regimen. Remarkably, most participants observed rapid decreases in their depressive symptoms, showcasing improvements of -6.1 at two hours and -9.6 by Day 10 on the Hamilton Depression Rating Scale-6 items (HAM-D6).

Key Metrics of Efficacy

Participants in the study reported substantial reductions in depression severity, as evidenced by the Montgomery Åsberg Depression Rating Scale (MADRS). A notable shift was observed, with improvements of -16.6 at four hours and -22.9 at Day 10. These outcomes reflect an encouraging response rate, with 50% of subjects achieving a 50% reduction in MADRS scores and over 63% reaching remission by the end of the treatment period.

Safety and Tolerability Profile

SPN-820 not only demonstrated efficacy but was also well-tolerated by the participants. The study reported an 80% decrease in suicidal ideation, a critical consideration when evaluating treatments for depression. The majority of adverse events encountered, including headache, nausea, and dizziness, were mild to moderate, with only a 2.5% discontinuation rate due to side effects.

A Promising Future

The Chief Medical Officer of Supernus, Dr. Jonathan Rubin, emphasized the potential of SPN-820 as a breakthrough in antidepressant therapy, citing its rapid action and the favorable tolerability profile. He noted the significance of these findings for patients who often struggle with the side effects associated with traditional depression treatments.

Understanding SPN-820 and Its Mechanism

SPN-820 is recognized as a first-in-class treatment, acting as an intracellular modulator of the mechanistic target of rapamycin complex 1 (mTORC1). This compound aims to enhance synaptic function in the brain and is designed for oral administration, bringing a potential rapid-onset response for those suffering from depression. Early clinical studies confirm that SPN-820 can signal efficacy as quickly as two hours after administration.

Ongoing Development and Future Studies

Supernus Pharmaceuticals is committed to furthering the development of SPN-820, with a Phase 2b clinical study currently underway involving approximately 227 adult patients with treatment-resistant depression. This continuation underscores their dedication to exploring new avenues for effective depression management.

About Supernus Pharmaceuticals, Inc.

Founded with a focus on CNS disorders, Supernus Pharmaceuticals has an extensive portfolio that includes treatments for epilepsy, migraine, and attention deficit hyperactivity disorder (ADHD), among others. The company strives to expand its offerings with innovative drug candidates aimed at various CNS conditions, including depression.

Frequently Asked Questions

What does the SPN-820 study focus on?

The SPN-820 study primarily assesses its effectiveness and safety in treating major depressive disorder.

How significant were the improvements in depressive symptoms?

Participants experienced rapid reductions in symptoms, with a substantial number achieving remission within 10 days.

Were there any serious side effects reported?

No severe adverse events were reported during the study; most effects were mild to moderate.

What is the mechanism of action of SPN-820?

SPN-820 modulates the mTORC1 pathway, enhancing synaptic function through an intracellular mechanism.

What are Supernus Pharmaceuticals' future plans for SPN-820?

The company is conducting a Phase 2b study to evaluate SPN-820 in patients with treatment-resistant depression, aiming to expand its therapeutic potential.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 514

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 391

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 182

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 225

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 350

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

HALiXPEDITE Revolutionizes Biologics Therapy Development Process

Updated Category News Views 147

HALiXPEDITE: Transforming the Future of Biologics Development HALIX, a prominent global healthcare Contract Development and Manufacturing Organization (CDMO), recently unveiled its innovative platform, HALiXPEDITE, at a notable conference. This platform is specifically designed to expedite the development of biologics therapies, focusing on a streamlined approach to...

Continue Reading
Day One Biopharmaceuticals to Share Q3 2025 Insights

Updated Category News Views 170

Day One Biopharmaceuticals to Present Q3 2025 Financial Results In a busy season for the biopharmaceutical industry, Day One Biopharmaceuticals (Nasdaq: DAWN) has announced it will host a live conference call and webcast aimed at reporting its financial results and outlining corporate progress for the third quarter of 2025. Conference Call Details The event is scheduled...

Continue Reading
Leica Biosystems Promotes DICOM Standards for Digital Pathology

Updated Category News Views 114

Leica Biosystems Promotes DICOM Standards for Digital Pathology Leica Biosystems, a prominent figure in anatomic pathology, has recently made waves in the medical field with a bold new initiative. By announcing the non-enforcement of their Digital Pathology DICOM (Digital Imaging and Communications in Medicine) patent portfolio, they aim to boost the implementation of...

Continue Reading
LYNPARZA: A Breakthrough in Early Breast Cancer Treatments

Updated Category News Views 288

Significant Survival Benefits with LYNPARZA in Breast Cancer Recent findings from the OlympiA Phase III trial bring exciting news for patients battling early breast cancer. AstraZeneca and Merck & Co., Inc.'s LYNPARZA (olaparib) has showcased profound improvements in survival rates among patients with germline BRCA-mutated HER2-negative high-risk early breast cancer. This...

Continue Reading
EuroDry Limited's Stock Experiences Volatility Amid Challenges

Updated Category News Views 229

EuroDry Limited Faces Stock Turmoil EuroDry Ltd. (NASDAQ: EDRY), a leading provider in drybulk shipping, has recently encountered a tumultuous phase, with its stock reaching a noteworthy low at $14.1. This decline marks a significant reflection on the year's challenges the company has faced, indicated by a -14.71% change over the past year. Market Conditions and...

Continue Reading